Home Cart Sign in  
Chemical Structure| 103577-45-3 Chemical Structure| 103577-45-3

Structure of Lansoprazole
CAS No.: 103577-45-3

Chemical Structure| 103577-45-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lansoprazole is an inhibitor of proton-pump. It can reduce the gastric acid production of stomach.

Synonyms: AG-1749; A-65006; Lansoprazole, AG-1749, Prevacid, Zoton, Agopton, Bamalite, Opiren

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lansoprazole

CAS No. :103577-45-3
Formula : C16H14F3N3O2S
M.W : 369.36
SMILES Code : O=S(CC1=NC=CC(OCC(F)(F)F)=C1C)C2=NC3=C(N2)C=CC=C3
Synonyms :
AG-1749; A-65006; Lansoprazole, AG-1749, Prevacid, Zoton, Agopton, Bamalite, Opiren
MDL No. :MFCD00866873
InChI Key :MJIHNNLFOKEZEW-UHFFFAOYSA-N
Pubchem ID :3883

Safety of Lansoprazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Lansoprazole (AG 1749) is an oral proton pump inhibitor that effectively suppresses gastric acid secretion. Additionally, Lansoprazole (AG 1749) demonstrates potent inhibition of neutral sphingomyelinase (N-SMase), making it a brain-penetrant exosome inhibitor[1][2].
Target
  • Proton Pump

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW 264.7 cells 1-2.5 μM 4 days Significantly increased the proportion of large osteoclasts PMC4703748
HEK293 cells 20 μM 30 minutes Enhances polyubiquitination of TRAF6 PMC4703748
Human mesenchymal stromal cells 20 μM 2 days Enhances nuclear accumulation of Runx2 and induces osteoblastogenesis PMC4703748
Human primary white adipocytes 10 μmol/L LPZ treatment induced the expression of thermogenic markers UCP1 and PPARGC1A PMC10985025
Mouse primary subcutaneous white adipocytes 10 μmol/L LPZ treatment significantly increased basal, maximal and proton leak respiration and elevated the expression of thermogenic genes PMC10985025
Mouse primary brown adipocytes 10 μmol/L LPZ treatment significantly increased basal, maximal and proton leak respiration and elevated the expression of thermogenic genes PMC10985025
MRC-5 lung fibroblasts 10 µM 72 hours Lansoprazole showed intracellular activity against Mycobacterium tuberculosis in MRC-5 lung fibroblasts with an IC50 of 1.47 µM PMC4510652
Human microvascular endothelial cells (HMVECs) 20 μM 24 hours To study the effect of PPIs on intracellular ADMA concentration, results showed PPIs increased intracellular ADMA by ~30% PMC3838201
NIH3T3 fibroblasts 160 μM 180 seconds To test the inhibitory effect of lansoprazole on swelling-dependent chloride channels (IClswell), results showed that lansoprazole could block IClswell with an IC50 of 160 μM. PMC1571856
Candida auris AR0390 40 µg/mL (108 µM/mL) LNP + 2 µg/mL AmB 6 hours To assess the killing kinetics of the AmB/LNP combination, lansoprazole restored the fungicidal properties of AmB against resistant C. auris within 6 hours. PMC10911247
Candida auris AR0390 16 µM/mL 24 hours To screen for drugs that enhance AmB's antifungal activity, lansoprazole was identified as a potent enhancer of AmB against C. auris AR0390. PMC10911247
Aβ42 fibrils 2.5–10 μM 750 s Evaluation of binding kinetics of lansoprazole with Aβ42 fibrils, showing multiple binding sites PMC11527973
ΑSyn fibrils 2.5–10 μM 750 s Evaluation of binding kinetics of lansoprazole with αSyn fibrils, showing multiple binding sites PMC11527973

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J male mice High-fat diet (HFD)-induced obesity model Subcutaneous injection 10 mg/kg Daily until the completion of the experiments LPZ treatment slowed body weight gain, reduced fat mass accumulation, increased energy expenditure, improved glucose tolerance and insulin sensitivity, and alleviated hepatic steatosis PMC10985025
BALB/c mice Acute tuberculosis model Oral 300 mg/kg Twice daily for 9 days Oral administration of lansoprazole sulfide significantly reduced the bacterial burden of Mycobacterium tuberculosis-infected mice PMC4510652
Sprague–Dawley rats Femoral fracture model Oral 7.5 mg/kg/day Once daily for 4 weeks Increased osteoblastogenesis and accelerated fracture healing PMC4703748
C57BL/6J mice Subcutaneous injection 30 mg/kg/day Once daily for 5 weeks To study the effect of lansoprazole on serum ADMA levels, results showed lansoprazole increased serum ADMA by ~20% PMC3838201
Female CD-1 mice Disseminated C. auris infection model Oral 300 mg/kg Once daily for two days To evaluate the therapeutic efficacy of the AmB/LNP combination in vivo, the combination significantly reduced fungal burden in the kidneys (1.7-log reduction) and improved mouse health. PMC10911247

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00299845 Gastroesophageal Reflux PHASE4 WITHDRAWN - Osaka University Hospital, Sui... More >>ta, Osaka, 565-0871, Japan Less <<
NCT00458614 Cystic Fibrosis PHASE1 COMPLETED 2025-04-07 Arkansas Children's Hospital L... More >>ittle Rock, Little Rock, Arkansas, 72202, United States Less <<
NCT00211614 Obstructive Sleep Apnea|Gastro... More >>esophageal Reflux Less << WITHDRAWN 2025-09-06 MetroHealth Medical Center, Cl... More >>eveland, Ohio, 44109, United States Less <<
NCT01512953 Coronary Stenting PHASE4 UNKNOWN 2025-08-13 University Hospital of Ferrara... More >>, Ferrara, ER, 44100, Italy Less <<
NCT00390390 Heartburn PHASE3 COMPLETED 2025-01-07 Sunbelt Research Group, Mobile... More >>, Alabama, 36608, United States|Arkansas Primary Care Clinic, Little Rock, Alaska, 72204, United States|Radiant Research, Chandler, Arizona, 85225, United States|Radiant Research - Scottsdale, Scottsdale, Arizona, 85251, United States|Edinger Medical Group, Fountain Valley, California, 92709, United States|Gaslamp Medical Center, San Diego, California, 92101, United States|Expresscare Clinical Research, Colorado Springs, Colorado, 80909, United States|Central Florida Clinical Trials inc., Altamonte Springs, Florida, 32714, United States|Tampa Bay Medical Research, Inc., Clearwater, Florida, 33761, United States|Health Awareness Inc., Jupiter, Florida, 33458, United States|University Clinical Research, Inc., Pembroke Pines, Florida, 33024, United States|Palm Beach Research, West Palm Beach, Florida, 33409, United States|Accelovance, Peoria, Illinois, 61602, United States|IRSI, Rockland, Massachusetts, 04841, United States|Prime Care Research, St. Louis, Missouri, 63031, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, 89104, United States|Urgentmed, South Bound Brook, New Jersey, 08880, United States|Wake research associates, Inc, Raleigh, North Carolina, 27612, United States|Piedmont Medical Research, Winston Salem, North Carolina, 27103, United States|Radiant Research, Cincinnati, Ohio, 45236, United States|Wells Institute For Health Awareness, Kettering, Ohio, 45429, United States|Toledo Center for Clinical Research, Sylvania, Ohio, 43560, United States|Durham Physicans, Durham, Pennsylvania, 19047, United States|2222 State Street, Nashville, Tennessee, 37203, United States|Wells Branch Medical Center, Austin, Texas, 78728, United States|Medical Edge Healthcare Group, Dallas, Texas, 75243, United States|Houston, Texas, 77002, United States|Clinical Trials Network, Houston, Texas, 77074, United States|Health Research of Hampton Roads, Newport News, Virginia, 23606, United States|Holston Medical Group, Weber City, Virginia, 24290, United States Less <<
NCT02151786 Gastric Ulcer, Duodenal Ulcer,... More >> Acute Stress Gastritis, and Acute Gastric Mucosal Lesions Less << COMPLETED 2025-03-10 -
NCT02099708 Gastric or Duodenal Ulcers COMPLETED 2025-03-14 -
NCT02099682 Gastric or Duodenal Ulcers COMPLETED 2025-01-14 -
NCT00220909 Patients Undergoing Elective C... More >>oronary Artery Bypass Graft Less << PHASE4 TERMINATED 2025-01-06 Temple University School of Me... More >>dicine, Philadelphia, Pennsylvania, 19140, United States Less <<
NCT01135368 Gastroesophageal Reflux PHASE4 COMPLETED 2025-09-08 -
NCT02170207 Acute Stress Ulcer and Acute G... More >>astric Mucosal Lesions Less << COMPLETED 2025-03-10 -
NCT01778101 Preterm Infants|Gastrointestin... More >>al Reflux Less << PHASE2 COMPLETED 2025-06-13 Seoul National University Chil... More >>dren's Hospital, Seoul, 110-740, Korea, Republic of Less <<
NCT01270308 Healthy PHASE1 COMPLETED 2025-12-08 Bioserve Clinical Research (P)... More >> Ltd, Balanagar, Hyderabad, 500 037, India Less <<
NCT01990339 Gastroesophageal Reflux Diseas... More >>e With Dyspepsia Symptoms Less << COMPLETED 2025-12-10 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.71mL

0.54mL

0.27mL

13.54mL

2.71mL

1.35mL

27.07mL

5.41mL

2.71mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories